Search Results - "Mangasarova, Y."

PB2154: TP53 GENE MUTATION DIVERSITY IN RUSSIAN PATIENTS WITH B‐CELL LYMPHOMAS by Biderman, B., Severina, N., Koroleva, D., Gabeeva, N., Belyaeva, A., Tatarnikova, S., Babaeva, F., Nesterova, E., Mangasarova, Y., Margolin, O., Bagova, M., Magomedova, A., Kravchenko, S., Obukhova, T., Zvonkov, E., Sudarikov, A.

Get full text

PB2089: ALGORITHM FOR SEVERE COVID‐19 RISK STRATIFICATION DEPENDING MONOCLONAL ANTI‐CD20 ANTIBODIES TREATMENT DURATION IN NON‐HODGKIN LYMPHOMA PATIENTS by Sychevskaya, K., Kravchenko, S., Babaeva, F., Misyurina, A., Korneeva, A., Abdulpatahov, A., Abdurashidova, R., Keniaykina, A., Sarakaeva, Z., Fastova, E., Gorenkova, L., Nesterova, E., Mangasarova, Y., Bagova, M., Margolin, O., Magomedova, A.

Get full text

P1207: MULTICENTER RANDOMIZED CONTROLLED (COMPARATIVE) OPEN PROSPECTIVE STUDY TO EVALUATE THE EFFICACY OF THE R‐DA‐EPOCH‐21 AND R‐MNHL‐BFM‐90 ± AUTO‐ HSCT PROGRAMS IN PATIENTS WITH DE NOVO DIFFUSE B‐CELL LAR by Magomedova, A., Kravchenko, S., Misyurina, A., Mangasarova, Y., Margolin, O., Fastova, E., Babaeva, F., Gorenkova, L., Bagova, M., Nesterova, E., Sychevskaya, K., Moiseeva, T., Kovrigina, A., Obukhova, T., Dvirnyk, V., Galtseva, I., Galuzyak, V., Maryina, S., Danishyan, K., Kostina, I., Sudarikov, A., Klyasova, G., Kulikov, S., Chabaeva, Y., Zinina, E., Kryuchkova, I., Sizikova, S., Sergeyevicheva, V., Ksenzova, T., Anikina, E., Shelekhova, T., Arzhanukhina, O., Kaplanov, K., Konstantinova, T., Serdyuk, O., Sychyova, T., Chagorova, T., Nechunayeva, I., Anchukova, L., Dzarasova, O., Parovichnikova, E., Savchenko, V.

Get full text

Follicular lymphoma. High-dose immunochemotherapy with autologous blood stem cell transplantation: Results of the first prospective study in Russia by Nesterova, E S, Kravchenko, S K, Mangasarova, Ya K, Baryakh, E A, Misyurina, A E, Vorobyev, V I, Plastinina, L V, Chernova, N G, Kovrigina, A M, Obukhova, T N, Klyasova, G A, Shevelev, A A, Kostina, I E, Gemdzhian, E G, Gaponova, T V, Vorobyev, A I

“…to evaluate the efficiency of high-dose chemotherapy (HDCT) with further autologous blood stem cell transplantation (auto-BSCT) in the first-line therapy of…”
Get full text